Tislelizumab Drug Asset Due Diligence Report 2026

This Tislelizumab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

930

Registered trials

591

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Tislelizumab can convert its Monoclonal antibody profile and PD-1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Tislelizumab (query alias: tislelizumab)
Modality / target	Monoclonal antibody; PD-1; PD-1 inhibitors
Highest global status	Approved
Originator	BeOne Medicines Ltd.
Active developers	BeOne Medicines Ltd., Glenmark Pharmaceuticals Ltd., Novartis AG

The MCP disease footprint includes Esophageal Carcinoma, PD-L1 positive Esophageal Squamous Cell Carcinoma, Locally Advanced Gastric Adenocarcinoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
ChiCTR2600128148	Phase 4	Not yet recruiting	39	Objective Response Rate（ORR）
NCT07700667	Phase 2	Not yet recruiting	120	Objective Response Rate (ORR)
CTR20262661	Phase 2	进行中（尚未招募）	120	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2; n=160; evaluation: not stated. Reported fields: ORR = 27.5 Percentage of Participants (95% Confidence Interval, 14.6 - 43.9); ORR: Risk Difference (RD) = -0.6(95% CI, -19.5 to 18.3); Risk Difference (RD) = -3.0(95% CI, -21.9 to 15.8); Risk Difference (RD) = 0.0(95% CI, -19.6 to 19.6); ORR = 27.5 Percentage of Participants (95% Confidence Interval, 14.6 - 43.9)

A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

Phase 1/2; n=113; evaluation: not stated. Reported fields: -; -; -

The Efficacy and Safety of Tislelizumab plus Anlotinib as First-line Treatment in Advanced Pulmonary Sarcomatoid Carcinoma: A Single-Arm Phase II Trial

Phase 2; n=29; evaluation: Positive. Reported fields: ORR = 55.17 % ( 35.69 - 73.55)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Tislelizumab addresses Esophageal Carcinoma, PD-L1 positive Esophageal Squamous Cell Carcinoma, Locally Advanced Gastric Adenocarcinoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 14 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2024-09-27	Anbogen Announces Drug Supply Collaboration with BeiGene to Evaluate Combination Therapy in Colorectal Cancer	Approved	Financial terms not disclosed
2024-05-21	Glenmark and BeiGene Enter into an Agreement for Marketing and Distribution of Tislelizumab and Zanubrutinib in India	Approved	Financial terms not disclosed
2023-09-19	Novartis statement on collaboration and license agreement for tislelizumab with BeiGene, Ltd.	Approved	US$650.0M upfront; US$1,550.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Methods for modulating glycosylation of tislelizumab or its derivatives”. The milestone feed surfaced a patent-application signal described as “Combination therapies using CDK4 inhibitors with PD-1 axis binding antagonists”. The milestone feed surfaced a patent-application signal described as “Interleukin-15, PD-1 Antibodies, and Taxanes in Non-Small Cell Lung Cancer”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO